FREMONT, Calif., April 27 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc.
(PDL) (Nasdaq: PDLI) today announced that it will release its financial
results for the first quarter of 2007 following the close of the U.S.
financial markets on Wednesday, May 2, 2007. PDL will hold a conference
call at 4:30 p.m. Eastern time on May 2, 2007 to discuss the company's
performance during the first quarter and provide an update on its strategy
and 2007 objectives.
The live webcast of the conference call will be available through the
PDL website: http://www.pdl.com. Please connect to this website at least 15
minutes prior to the live webcast to allow time for any software download
that may be needed to hear the webcast. Financial and statistical
information to be discussed in the call will be available on the PDL
website immediately prior to the commencement of the call. A replay will be
available at http://www.pdl.com starting approximately one hour after completion
of the webcast.
An audio replay will also be available by telephone from approximately
6:30 p.m. Eastern time on May 2, 2007 through 6:30 p.m. Eastern time on
June 2, 2007. To access the replay, dial 800-642-1687 from inside the U.S.
and 706-645-9291 from outside the U.S.; enter conference ID number 5721150.
About PDL BioPharma
PDL BioPharma, Inc. is a biopharmaceutical company focused on
discovering, developing and commercializing innovative therapies for severe
or life- threatening illnesses. Commercially focused in the acute-care
hospital setting, PDL markets and sells its portfolio of leading products
in the United States and Canada. A pioneer of antibody humanization
technology, PDL promotes this technology through licensing agreements and
clinical development of its own diverse pipeline of investigational
compounds. PDL's research platform centers on the discovery and development
of antibodies to treat cancer and autoimmune diseases. For more
information, please visit http://www.pdl.com.
NOTE: PDL BioPharma and the PDL logo are considered trademarks of PDL
BioPharma, Inc.
SOURCE PDL BioPharma, Inc.
 back to top
Related links:
http://www.pdl.com/
CONTACT:
Ami Knoefler, Corporate and Investor
Relations, +1-510-284-8851, ami.knoefler@pdl.com, or Jean Suzuki,
Investor Relations, +1-510-574-1550, or jean.suzuki@pdl.com
|
